Yoshinao Kobayashi
Overview
Explore the profile of Yoshinao Kobayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1000
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Becker N, Franz N, Eguchi A, Wagner A, Sturm R, Rinderknecht H, et al.
Front Immunol
. 2024 Jun;
15:1390380.
PMID: 38933277
Background: Extracellular particles (EPs), particularly extracellular vesicles, play a crucial role in regulating various pathological mechanisms, including immune dysregulations post-trauma. Their distinctive expression of cell-specific markers and regulatory cargo such...
2.
Iwasa M, Sugimoto R, Eguchi A, Tamai Y, Shigefuku R, Fujiwara N, et al.
Eur J Gastroenterol Hepatol
. 2024 Mar;
36(6):793-801.
PMID: 38526942
Background/aims: Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. We previously reported that pemafibrate significantly improves liver function, serum triglyceride...
3.
Kobayashi Y, Eguchi A, Imami K, Tempaku M, Izuoka K, Takase T, et al.
J Mol Med (Berl)
. 2023 Oct;
102(1):23-38.
PMID: 37874387
Obesity of children and adolescents (OCA) is often accompanied by metabolic syndrome (MetS), which often leads to adult obesity and subsequent complications, yet the entire pathophysiological response is not fully...
4.
Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Fujiwara N, et al.
Intern Med
. 2023 May;
63(1):31-41.
PMID: 37225491
Objective Zinc-α2-glycoprotein (ZAG) is secreted by various organs, such as liver, kidney and adipose tissue, is involved in lipolysis, and may contribute to the pathogenesis of chronic liver disease (CLD)....
5.
Sugimoto R, Iwasa M, Eguchi A, Tamai Y, Shigefuku R, Fujiwara N, et al.
Front Med (Lausanne)
. 2023 Feb;
10:1073025.
PMID: 36824614
Background/aims: Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. Pemafibrate was reported to reduce ALT in non-alcoholic fatty liver disease...
6.
Kobayashi Y, Sunada Y
Chem Sci
. 2023 Feb;
14(5):1065-1071.
PMID: 36756342
The use of metal hydrides such as NaBH as hydrogen-storage materials has recently received substantial research attention on account of the worldwide demand for the development of efficient hydrogen-production, -storage,...
7.
Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto R, Tanaka H, et al.
Eur J Gastroenterol Hepatol
. 2022 Nov;
34(12):1269-1276.
PMID: 36317773
Background: Nutritional status and skeletal muscle mass affect the prognosis of hepatocellular carcinoma (HCC). Nutritional status is closely associated with skeletal muscle mass. Here, we investigate the effect of controlling...
8.
Tamai Y, Eguchi A, Shigefuku R, Kitamura H, Tempaku M, Sugimoto R, et al.
Elife
. 2022 Oct;
11.
PMID: 36206032
Background: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few...
9.
Eguchi A, Iwasa M, Tamai Y, Yamada M, Okuno K, Shigefuku R, et al.
Front Oncol
. 2022 Sep;
12:993705.
PMID: 36081568
Background: Fragmented cytokeratin 18 (fCK18) is released from damaged hepatocytes undergoing apoptosis and is recognized as a liver condition biomarker. We have developed a highly sensitive serum fCK18 CLEIA and...
10.
Eguchi A, Iwasa M, Yamada M, Tamai Y, Shigefuku R, Hasegawa H, et al.
Hepatol Commun
. 2022 Apr;
6(8):1987-1999.
PMID: 35485207
Caspase-generated fragmented cytokeratin 18 (fCK18) is recognized as a useful noninvasive biomarker in the diagnosis of nonalcoholic fatty liver disease (NAFLD), particularly nonalcoholic steatohepatitis (NASH). However, fCK18 measurement is not...